BLACK FRIDAY EARLY — BOGO 50% SITEWIDE

Elamipretide (SS-31): What It Is, What Research Has Studied, and What the Evidence Actually Shows

By the Ageless Humans editorial team · Updated 2026-11-14 · 6 min read

Elamipretide (also called SS-31) is a small synthetic peptide that goes into mitochondria and binds cardiolipin, a fat molecule that helps keep the cell's energy machinery working. It has been studied mainly as a prescription drug candidate for rare mitochondrial conditions, and also in aging research in animals. Human results are mixed. It is an injectable drug compound, not a dietary supplement, and its 'benefits' for healthy aging in people have not been established.

What Is Elamipretide (SS-31)?

Elamipretide is a four-amino-acid peptide built to target mitochondria, the structures that make most of a cell's usable energy. It started as one of the Szeto-Schiller (SS) peptides, named for the researchers who first described the family. You may also see it called SS-31, MTP-131, or Bendavia in older papers. Stealth BioTherapeutics later developed it as a drug candidate.

The peptide alternates positively charged amino acids with aromatic (ring-shaped) ones. Research suggests this pattern lets it cross cell membranes and collect at the inner mitochondrial membrane, where the energy-making work happens. Most compounds can't reach that spot in useful amounts.

Two facts frame everything below:

  • It is a pharmaceutical compound. In clinical research it has been given by injection under the skin or by IV, not as a capsule.
  • It is not a dietary supplement. No legitimate supplement contains elamipretide, and products sold online as "SS-31" are usually labeled "for research use only."

For a broader primer on how peptides work in the body, see our guide on what peptides are. For a quick reference card on this compound, visit the elamipretide (SS-31) peptide profile.

How SS-31 Works: The Cardiolipin Mechanism

SS-31's proposed mechanism is binding to cardiolipin, a phospholipid found almost only in the inner mitochondrial membrane. Cardiolipin acts like scaffolding. It helps hold the folded inner membrane (the cristae) in shape and helps anchor the protein complexes of the electron transport chain, the assembly line that turns food energy into ATP.

When cardiolipin is damaged or oxidized, research suggests the assembly line becomes less efficient. Electrons "leak," more reactive oxygen species form, and ATP output may drop. Researchers have studied cardiolipin changes in aging tissue and in several mitochondrial conditions.

The working hypothesis for elamipretide goes like this:

1. It concentrates at the inner membrane and associates with cardiolipin. 2. It may help stabilize cristae structure and the organization of electron transport proteins. 3. It may improve electron flow, which could mean more efficient ATP production and less oxidant generation at the source.

That last point is what sets SS-31 apart from classic antioxidants. Standard antioxidants try to neutralize free radicals after they form. SS-31 is studied for its potential to reduce how many form in the first place by supporting the machinery itself. This mechanism is well supported in lab and animal studies. Whether it produces meaningful clinical outcomes in people is a separate question, covered below.

What Has Elamipretide Been Studied For?

Elamipretide has been studied mostly in rare inherited mitochondrial conditions, plus some cardiovascular, eye, and aging research. Here is the landscape, with research context kept separate from proven benefit:

  • Barth syndrome: This rare genetic condition directly involves abnormal cardiolipin, which makes it the most mechanism-matched target. It has been a central focus of the drug's clinical development and regulatory review.
  • Primary mitochondrial myopathy: Researchers ran clinical trials looking at exercise capacity and fatigue in adults with inherited mitochondrial muscle conditions.
  • Heart function: Early-stage studies looked at heart failure settings and ischemia-reperfusion (the stress tissue experiences when blood flow returns after an interruption).
  • Eye health: Researchers have examined it in age-related retinal conditions because retinal cells have very high energy demands.
  • Aging biology: Academic labs have given SS-31 to aged mice and measured heart and skeletal muscle function, mitochondrial efficiency, and related markers.

The pattern is clear. Researchers reach for SS-31 wherever mitochondrial dysfunction appears to drive the problem. That focus is a strength of the research program, and it also explains why results vary so much from one setting to the next.

The Aging Research: Why Longevity Circles Pay Attention

The longevity interest in SS-31 comes mostly from animal studies, where aged mice given the peptide showed improvements in several measures of muscle and heart function. Researchers reported that older animals' mitochondria appeared to work more efficiently after treatment. In some studies, tissue function moved toward patterns seen in younger animals.

This matters for aging science because mitochondrial decline is one of the most widely discussed hallmarks of aging. Researchers have described lower energy output, more oxidative stress, and weaker cellular repair capacity as tissues get older. A compound that appears to support the energy machinery directly is a useful research tool for testing how much of that decline can be changed.

Read those findings carefully, though:

  • Mice are not people. Many interventions that look strong in aged rodents never translate to humans.
  • The studies measure function, not lifespan. Better muscle performance in old mice is not the same as living longer.
  • No large human trials have tested SS-31 for healthy aging. Its human trials have enrolled people with specific medical conditions, not healthy adults looking to age well.

The Honest Evidence State in Humans

Human evidence for elamipretide is mixed: some trials reported encouraging signals, and at least one major late-stage trial did not meet its primary goals. A late-stage trial in adults with primary mitochondrial myopathy was reported to have missed its primary endpoints. That was a significant setback, and it shifted development toward narrower populations where the cardiolipin link is strongest.

In Barth syndrome research, investigators reported signals in some functional measures, and the compound moved through FDA review for that use. Its regulatory status has changed over time. If that matters to you, check the FDA's current listings rather than relying on secondhand summaries, including this one.

Here is what can fairly be said:

  • Mechanism: Strong preclinical support for cardiolipin binding and mitochondrial effects.
  • Animal aging data: Interesting and repeatable across several labs, but limited to function, not longevity.
  • Human clinical data: Limited to specific conditions, with inconsistent results across trials.
  • Healthy-aging use in people: Not established. No trial supports it.

In trials, the most commonly reported issue was injection-site reactions. Long-term safety data in healthy people does not exist because healthy people haven't been studied.

Elamipretide vs. Other Peptides and Bioregulators

SS-31 belongs in a different category from most peptides people discuss for wellness. It is an engineered drug compound designed for one intracellular target. Many wellness peptides, by contrast, are fragments of naturally occurring proteins studied for broader signaling roles.

A few useful contrasts:

  • SS-31 vs. MOTS-c: Both come up in "mitochondrial peptide" conversations, but they are different molecules. MOTS-c is encoded by mitochondrial DNA and is studied as a metabolic signaling peptide. SS-31 is synthetic and acts structurally at the inner membrane.
  • SS-31 vs. bioregulators: Short-chain bioregulator peptides are studied for tissue-specific gene-expression support, which is a very different hypothesis. Our explainer on what bioregulators are covers that category.
  • SS-31 vs. recovery peptides like BPC-157 and TB-500: These are studied mainly for tissue recovery and repair signaling, not mitochondrial structure.

The short version: "peptide" describes a molecule's size and building blocks, not what it does. Each compound needs to be judged on its own evidence.

Should You Try SS-31? What to Know Before Going Further

For healthy adults, SS-31 is not a reasonable self-experiment. It is an injectable investigational drug compound. Its human data is limited to specific medical conditions. And the online products sold as "SS-31" carry real quality risks.

Specifically:

  • "Research use only" vendors are not making products for human use. Identity, purity, sterility, and dose accuracy are often unverified.
  • Injectables from unregulated sources add risks of their own, including contamination.
  • If you have a diagnosed mitochondrial condition, the right path is a specialist and, where appropriate, a formal clinical trial.

If your real goal is supporting everyday energy, recovery, and healthy aging, the fundamentals still have the strongest evidence: training (especially combined endurance and resistance work), sleep, protein intake, and metabolic health. Quality-controlled supplements can play a supporting role. They should be judged on their own evidence, not borrowed from a drug candidate's headlines.

Related reading & products

Frequently asked questions

What is elamipretide (SS-31) used for?+

Elamipretide (SS-31) is an investigational, mitochondria-targeting peptide developed as a prescription drug candidate. It has been studied mainly in rare inherited mitochondrial conditions such as Barth syndrome and primary mitochondrial myopathy. Researchers have also explored it in heart, eye, and animal aging research. It is not a dietary supplement and has not been established for healthy aging in people.

How does SS-31 work?+

SS-31 collects at the inner mitochondrial membrane and binds cardiolipin, a phospholipid that helps hold the cell's energy-producing machinery together. Research suggests this may stabilize mitochondrial structure, improve electron flow, and reduce oxidant production at the source. The mechanism is well supported in lab and animal studies. Its clinical effects in humans are less consistent.

Is elamipretide FDA approved?+

Elamipretide has been developed and reviewed as a prescription drug, primarily for Barth syndrome, a rare genetic mitochondrial condition. Its regulatory status has changed over time, so check the FDA's current listings for the latest status. It is not approved as a dietary supplement or for general anti-aging use.

Does SS-31 work for anti-aging?+

Studies in aged mice reported improvements in measures of muscle and heart function and in mitochondrial efficiency. Those findings measure tissue function, not lifespan. No human trials have tested SS-31 for healthy aging, so any anti-aging benefit in people remains unproven.

Can you take SS-31 orally?+

In clinical research, elamipretide has been given by injection under the skin or by IV, not as a pill. Oral SS-31 products have not been established as effective or reliably absorbed. Products sold online as oral or injectable SS-31 are typically labeled "research use only" and are not made for human consumption.

What are the side effects of elamipretide?+

In clinical trials, the most commonly reported issue was injection-site reactions. Because the human trials enrolled people with specific medical conditions, there is no long-term safety data in healthy adults. Products from unregulated research-chemical vendors carry additional risks, including uncertain purity and contamination.

Keep reading